Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/4977
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIcard, Philippe-
dc.contributor.authorLoi, Mauro-
dc.contributor.authorWu, Zherui-
dc.contributor.authorGinguay, Antonin-
dc.contributor.authorLincet, Hubert-
dc.contributor.authorRobin, Edouard-
dc.contributor.authorCoquerel, Antoine-
dc.contributor.authorBerzan, Diana-
dc.contributor.authorFournel, Ludovic-
dc.contributor.authorAlifano, Marco-
dc.date.accessioned2023-06-15T02:50:21Z-
dc.date.available2023-06-15T02:50:21Z-
dc.date.issued2021-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/4977-
dc.description.abstractThe tumor microenvironment is a complex mix of cancerous and noncancerous cells (especially immune cells and fibroblasts) with distinct metabolisms. These cells interact with each other and are influenced by the metabolic disorders of the host. In this review,we discuss how metabolic pathways that sustain biosynthesis in cancer cells could be targeted to increase the effectiveness of cancer therapies by limiting the nutrient uptake of the cell, inactivating metabolic enzymes (key regulatory ones or those linked to cell cycle progression), and inhibiting ATP production to induce cell death. Furthermore, we describe how the microenvironment could be targeted to activate the immune response by redirecting nutrients toward cytotoxic immune cells or inhibiting the release of waste products by cancer cells that stimulate immunosuppressive cells.We also examine metabolic disorders in the host that could be targeted to inhibit cancer development. To create future personalized therapies for targeting each cancer tumor, novel techniques must be developed, such as new tracers for positron emission tomography/computed tomography scan and immunohistochemical markers to characterize the metabolic phenotype of cancer cells and their microenvironment. Pending personalized strategies that specifically target all metabolic components of cancer development in a patient, simple metabolic interventions could be tested in clinical trials in combination with standard cancer therapies, such as short cycles of fasting or the administration of sodium citrate or weakly toxic compounds (such as curcumin, metformin, lipoic acid) that target autophagy and biosynthetic or signaling pathways.en_US
dc.language.isoen_USen_US
dc.publisherAdvances in Nutritionen_US
dc.relation.ispartofseriesReview;1461-1480-
dc.subjectmetabolismen_US
dc.subjectglycolysisen_US
dc.subjecttumor microenvironmenten_US
dc.subjectimmunityen_US
dc.subjectbody compositionen_US
dc.subjectdrug resistanceen_US
dc.titleMetabolic Strategies for Inhibiting Cancer Developmenten_US
dc.typeArticleen_US
Appears in Collections:VOL 12 NO 4 (2021)

Files in This Item:
File Description SizeFormat 
1461-1480.pdf2.12 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.